NRG-GU013

Open to Accrual

Return to Protocol Table

The Phase III ‘High Five Trial’ Five Fraction Radiation For High-Risk Prostate Cancer

Principal Investigator

Karen E. Hoffman,

Status

Open to Accrual

Date Opened To Accrual

November 13 2023

Disease Site

Genitourinary [GU]

Prostate

Phase

III

Developmental Therapeutics

Primary Objective

To compare metastasis-free survival, determined usingconventional imaging, between men with high-risk prostate cancer randomized toultrahypofractionation (SBRT) to those randomized to moderate hypofractionationand conventional fractionation.

Patient Population

Pathologically proven diagnosis of adenocarcinoma ofprostate cancer and are high-risk disease.

Target Accrual

1209

Protocol Documents

Available via the National Cancer Institute (NCI) Cancer Trials Support Unit (CTSU) website.

Patient Study Webpage

To learn more about this study, visit the Patient Study Webpage.

Support NRG Oncology.
Help Our Cause.

We are a leading protocol organizations within the National Clinical Trials Network and we seek to improve the lives of cancer patients by conducting practice-changing, multi-institutional clinical and translational research. Learn More

Donate Today

NRG Oncology Foundation, Inc, is a nonprofit, tax-exempt foundation. Donations to NRG Oncology help us conduct this important mission, and are tax-deductible to the extent permitted by law.